文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌经会阴超声引导放疗的医生报告毒性与患者报告生活质量

Physician reported toxicities and patient reported quality of life of transperineal ultrasound-guided radiotherapy of prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-09-21

本研究评估164例前列腺癌患者接受经会阴超声(TPUS)引导放疗的毒性与生活质量,其中112例提供前瞻性生活质量数据。中位随访19个月时,急性2级胃肠和泌尿毒性分别为8.6%和21.5%,晚期2级胃肠毒性在27个月时为2.2%,未见晚期2级泌尿毒性,患者报告生活质量总体耐受良好。

要点

  • 放疗结束时的急性2级胃肠毒性和泌尿毒性发生率分别为8.6%和21.5%。
  • 27个月时晚期2级胃肠毒性发生率为2.2%,51个月时仅1例,未见晚期2级泌尿毒性。
  • 患者主要经历疲劳、疼痛及肠道和泌尿症状的急性临床相关恶化,多数在3个月时恢复正常并保持稳定。

核心结论

  • TPUS引导放疗在医生报告的毒性极低和患者报告的生活质量满意方面显示出有希望的结果。

研究设计与样本

  • 本研究纳入164例接受经会阴超声(TPUS)引导放疗的前列腺癌患者,其中112例在前瞻性评估中提供了生活质量数据。
  • 放疗技术采用容积旋转调强放疗(VMAT)或调强放疗(IMRT)。
  • 医生使用CTCAE v5.0评估急性和晚期胃肠(GI)及泌尿生殖(GU)毒性。
  • 患者报告生活质量采用EORTC QLQ-C30、-PR25和IPSS评估,评估时间点为放疗前、放疗结束时、放疗后3个月及随后每年一次。
  • 每次随访时评估前列腺特异性抗原(PSA)。

主要发现

  • 治疗前中位PSA为7.9 ng/mL(范围:1.8-169 ng/mL),中位随访19个月(范围:3-82个月)时中位PSA降至0.22 ng/mL。
  • 放疗结束时急性2级胃肠毒性和泌尿毒性分别发生于8.6%和21.5%的患者。
  • 27个月时2.2%的患者发生晚期2级胃肠毒性,51个月时仅1例患者发生;在这些时间点未报告晚期2级泌尿毒性。
  • 生活质量评分显示治疗耐受良好,患者主要经历疲劳、疼痛以及肠道和泌尿症状的急性临床相关恶化。
  • 大多数症状在3个月时恢复正常并 thereafter 保持稳定;整体功能在放疗结束时出现类似下降但随时间改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aims to address therapy-related toxicities and quality of life in prostate cancer patients undergoing transperineal ultrasound (TPUS) guided radiotherapy (RT). METHODS: Acute and late gastrointestinal (GI) and genitourinary (GU) toxicities were assessed by physicians using CTCAE v5.0. Patient-reported quality of life outcomes were evaluated using EORTC QLQ-C30, -PR25 and IPSS. We utilized Volumetric Modulated Arc Therapy (VMAT) or intensity modulated radiation therapy (IMRT) as the RT technique for this study. The assessments were carried out before RT, at RT end, 3 months after RT and subsequently at 1-year intervals. Prostate-specific antigen (PSA) was also evaluated at each follow-up. RESULTS: In this study, a total of 164 patients were enrolled, while among them, 112 patients delivered quality-of-life data in a prospective evaluation. The median pre-treatment PSA was 7.9 ng/mL (range: 1.8-169 ng/ml). At the median follow-up of 19 months (3-82 months), the median PSA decreased to 0.22 ng/ml. Acute grade II GI and GU toxicities occurred in 8.6 % and 21.5 % patients at RT end. Regarding late toxicities, 2.2 % patients experienced grade II GI toxicities at 27 months and only one patient at 51 months, whereas no grade II GU late toxicities were reported at these time points. Quality of life scores also indicated a well-tolerated treatment. Patients mainly experienced acute clinically relevant symptoms of fatigue, pain, as well as deterioration in bowel and urinary symptoms. However, most symptoms normalized at 3 months and remained stable thereafter. Overall functioning showed a similar decline at RT end but improved over time. CONCLUSION: The outcomes of TPUS-guided RT demonstrated promising results in terms of minimal physician-reported toxicities and satisfactory patient-reported QoL.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ma J, Rogowski P, Trapp C, et al. Physician reported toxicities and patient reported quality of life of transperineal ultrasound-guided radiotherapy of prostate cancer. Clin Transl Radiat Oncol. 2024. PMID: 39381629. doi:10.1016/j.ctro.2024.100868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。